LRLossReserves.com
Subscribe
Back to The WireHealth Plans

Cigna Drops GLP-1 for Own Staff as Employer Coverage Plateaus

Cigna will end GLP-1 weight-loss coverage for its 67,700 employees on July 1, the highest-profile signal that employer tolerance for GLP-1 pharmacy costs has peaked, forcing self-insured plan sponsors to model two divergent reserve scenarios.

By Sam, EditorJune 2026 · 3 min read

Cigna will end GLP-1 weight-loss drug coverage for its approximately 67,700 employees effective July 1, according to an internal email reported by Reuters on June 2. Coverage for GLP-1 medications prescribed for type 2 diabetes continues. Cigna cited expanding availability and new options as the rationale, directing affected employees to cash-pay channels including manufacturer sites. The decision does not affect coverage Cigna administers for external clients.

The timing is notable. A Business Group on Health survey of 105 self-funded employers, published in May, found that 67% currently cover GLP-1s for weight management, but only 72% of those plan to continue in 2027. Nearly 80% of respondents reported that GLP-1s are driving healthcare cost increases, and 87% expect oral formulations to push utilization higher. The 840% surge in GLP-1 PMPM costs from 2022 to 2024 explains why executive leadership is now involved in coverage decisions at nearly 80% of surveyed employers.

Who it affects

Self-insured employers covering GLP-1 medications for weight management, their stop-loss carriers, and any plan sponsor approaching a renewal cycle where the GLP-1 coverage decision has not yet been made. Hospital systems, universities, and municipalities running self-funded plans face the same binary choice Cigna just made for itself.

The reserve mechanism: two scenarios, one deadline

For self-insured health plans, Cigna’s decision crystallizes a plan design fork that produces two distinct reserve paths.

Scenario one: drop coverage. Pharmacy PMPM declines within one quarter as GLP-1 scripts roll off. But untreated obesity does not stay on the pharmacy line; it migrates to the medical triangle. Type 2 diabetes onset, cardiovascular events, and joint replacements emerge over two to three development years. Plans that dropped coverage in early 2025 renewal cycles are beginning to see this lag in their medical claims data. The comorbidity cost concentration that Sun Life documented above $3 million shows where this deferred severity surfaces: not in the pharmacy bucket, but in catastrophic medical claims that breach stop-loss thresholds.

Scenario two: keep coverage. Utilization accelerates. Oral formulations like Lilly’s Foundayo at $149 per month collapse the cost barrier that injectable pricing created. The 87% of employers expecting higher demand from oral GLP-1s are pricing in a utilization curve that bends upward, not flat. With nine additional obesity drugs targeting FDA approval by 2027, the eligible population widens even as per-unit costs eventually compress. Adverse selection compounds the problem: if competing employers in your labor market drop GLP-1 access, employees who need the drugs concentrate in plans that still cover them.

Stop-loss carriers are repricing for both paths. Specific attachment points that assumed a certain pharmacy severity distribution are stale under either scenario. Stop-loss claim trends already running 9 points above the five-year average leave little margin for a plan design change that reshapes the severity curve.

What this means for your next review

The question for your next reserve study is not whether to cover GLP-1s. It is whether your actuary has modeled both scenarios and quantified the difference. Three items for the agenda:

  1. Request separate IBNR projections under a coverage continuation and a coverage discontinuation assumption. The pharmacy and medical components move in opposite directions; a single blended estimate masks the exposure.
  2. Ask what medical comorbidity cost emergence your actuary is projecting over the next three development years if coverage is dropped. If the answer is “none,” the model is missing the lag.
  3. Confirm that your stop-loss renewal pricing reflects your actual coverage decision, not last year’s plan design. Attachment points set against a prior year’s pharmacy severity are not calibrated for either scenario.

Cigna’s July 1 effective date creates the first large-scale natural experiment in GLP-1 coverage withdrawal from a major employer. Early Q3 2026 claims data will show whether pharmacy PMPM drops as expected and whether medical utilization for obesity-related conditions begins to shift.

Sources

More from The Wire
Health Plans

FDA Pediatric Casgevy Approval Tests Stop-Loss Reserves

FDA's July 1 supplemental approval expanded Casgevy to patients aged 2 and older, moving a one-time gene therapy exposure into younger covered dependents and forcing self-funded plans to revisit stop-loss recovery timing.

3 min read
Health Plans

Sixth Circuit PBM Ruling Tests Pharmacy Claim Reserves

The Sixth Circuit affirmed ERISA preemption of Tennessee PBM network and cost-sharing rules as applied to McKee Foods' self-funded health plan. The reserve issue is whether pharmacy channel controls still support the expected claim ratio and unpaid-claim completion factors.

3 min read
Health Plans

CMS Drug Model Tests Health Plan Stop-Loss Assumptions

CMS has set a September 10, 2026 state application deadline for the GENEROUS Medicaid drug model. Self-insured employers are outside the model, but its public-payer net-price signal can distort pharmacy trend and stop-loss severity assumptions if plans do not tie benchmarks back to their own PBM contracts.

3 min read